請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77041完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林君榮(Chun-Jung Lin) | |
| dc.contributor.author | Fang-Yi Chou | en |
| dc.contributor.author | 周芳儀 | zh_TW |
| dc.date.accessioned | 2021-07-10T21:44:21Z | - |
| dc.date.available | 2021-07-10T21:44:21Z | - |
| dc.date.copyright | 2021-02-25 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-02-02 | |
| dc.identifier.citation | Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-10.
Arzberger T, Krampfl K, Leimgruber S, Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study. J Neuropathol Exp Neurol 1997; 56: 440-54. Amboni M, Barone P, Hausdorff JM. Cognitive contributions to gait and falls: evidence and implications. Mov Disord 2013; 28: 1520-33. Ballesteros-Yáñez I, Castillo CA, Merighi S, Gessi S. The Role of Adenosine Receptors in Psychostimulant Addiction. Front Pharmacol 2018; 8: 985. Bethesda. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors. In: LiverTox Clinical and Research Information on Drug-Induced Liver Injury [online]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK548187/ Blum D, Chern Y, Domenici MR, Buée L, Lin CY, Rea W, et al. The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. J Caffeine Adenosine Res 2018; 8: 43-58. Boison D, Chen JF, Fredholm BB. Adenosine signaling and function in glial cells. Cell Death Differ 2010; 17: 1071-82. Bossy-Wetzel E, Petrilli A, Knott AB. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 2008; 31:609-16. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 2009; 106: 22480-5. Camici M, Garcia-Gil M, Pesi R, Allegrini S, Tozzi MG. Purine-Metabolising Enzymes and Apoptosis in Cancer. Cancers (Basel). 2019; 11: 1354. Cepeda C, Tong XP. Huntington's disease: From basic science to therapeutics. CNS Neurosci Ther 2018; 24: 247-49. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007; 83: 228-48. Chen YJ, Cheng FC, Sheu ML, Su HL, Chen CJ, Sheehan J, et al.Detection of subtle neurological alterations by the Catwalk XT gait analysis system. J Neuroeng Rehabil 2014; 11: 62. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 2005; 93: 310-20. Cross AJ, Slater P, Reynolds GP. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neurosci Lett 1986; 67: 198-202. Cunha RA. How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem 2016; 139: 1019-55. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69. Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, et al. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease. Neurobiol Dis. 2014; 71: 193-204. Frank S. Treatment of Huntington's disease. Neurotherapeutics 2014; 11: 153-60. Dai SS, Zhou YG, Li W, An JH, Li P, Yang N, et al. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 2010; 30: 5802-10. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-48. D'Amelio M, Cavallucci V, Cecconi F. Neuronal caspase-3 signaling: not only cell death. Cell Death Differ 2010; 17:1104-14. D'Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: beyond apoptosis. Trends Neurosci 2012; 35: 700-9. Dragatsis I, Goldowitz D, Del Mar N, Deng YP, Meade CA, Liu L, et al. CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis 2009; 33: 315-30. Doyle A, McGarry MP, Lee NA, Lee JJ. The construction of transgenic and gene knockout/knockin mouse models of human disease. Transgenic Res 2012; 21: 327-49. Estrada Sánchez AM, Mejía-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008; 39: 265-76. Estrada-Sánchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009; 34: 78-86. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010; 19: 3053-67. Figiel M, Szlachcic WJ, Switonski PM, Gabka A, Krzyzosiak WJ. Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol 2012; 46: 393-429. Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci 2004; 7: 1233-41. Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-38 Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis 2004; 17: 77-88. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97: 505-19. Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, Wallace DC. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 1997; 16: 226-34. Gregorian C, Nakashima J, Le Belle J, Ohab J, Kim R, Liu A. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci 2009; 29: 1874-86. Guitart X, Bonaventura J, Rea W, Orru M, Cellai L, Dettori I, et al. Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. Neurobiol Dis 2016; 96: 47-53. Hansen JE, Tse CM, Chan G, Heinze ER, Nishimura RN, Weisbart RH. Intranuclear protein transduction through a nucleoside salvage pathway. J Biol Chem 2007; 282: 20790-3. Hoffmann-La Roche (Switzerland). (2019, Jan - ). A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease. Identifier NCT03761849. https://www.clinicaltrials.gov/ct2/show/NCT03761849?term=NCT03761849 draw=2 rank=1 Holper L, Lan MJ, Brown PJ, Sublette EM, Burke A, Mann JJ. Brain cytochrome-c-oxidase as a marker of mitochondrial function: A pilot study in major depression using NIRS. Depress Anxiety 2019; 36: 766-79. Hoshino A, Wang WJ, Wada S, McDermott-Roe C, Evans CS, Gosis B, et al. The ADP/ATP translocase drives mitophagy independent of nucleotide exchange. Nature 2019; 575: 375-9. Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. Hum Mol Genet 2013; 22:1826-42. Ibrahim MMH, Bheemanapally K, Sylvester PW, Briski KP. Sex-specific estrogen regulation of hypothalamic astrocyte estrogen receptor expression and glycogen metabolism in rats. Mol Cell Endocrinol 2020; 504:110703. Ipata PL. Origin, utilization, and recycling of nucleosides in the central nervous system. Adv Physiol Educ 2011a; 35: 342-6. Ipata PL, Camici M, Micheli V, Tozz MG. Metabolic network of nucleosides in the brain. Curr Top Med Chem 2011b; 11: 909-22. Institut National de la Santé Et de la Recherche Médicale (France). (2015, Jun – 2020, Dec). A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease. Identifier NCT02453061. https://www.clinicaltrials.gov/ct2/show/NCT02453061?term=NCT02453061 draw=2 rank=1 Jin YN, Johnson GV. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr 2010; 42: 199-205. Jodeiri FM, Ghaedi K. Huntington's Disease and Mitochondria. Neurotox Res 2017; 32: 518-29. Johri A, Chandra A, Flint Beal M. PGC-1α, mitochondrial dysfunction, and Huntington's disease. Free Radic Biol Med 2013; 62: 37-46. Ju TC, Chen HM, Chen YC, Chang CP, Chang C, Chern Y. AMPK-alpha1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease. Biochim Biophys Acta 2014; 1842: 1668-80. Ju TC, Lin YS, Chern Y. Energy dysfunction in Huntington's disease: insights from PGC-1alpha, AMPK, and CKB. Cell Mol Life Sci 2012; 69: 4107-20. Ju TC, Chen HM, Tin JT, Lin CP, Chang WC, Chang JJ, et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol 2011; 194: 209-27. Kao YH, Lin MS, Chen CM, Wu YR., Chen HM, Lai HL, et al. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. Hum Mol Genet 2017; 26: 467-78. Khakh BS, Beaumont V, Cachope R, Munoz-Sanjuan I, Goldman SA, and Grantyn R. Unravelling and Exploiting Astrocyte Dysfunction in Huntington's Disease. Trends Neurosci 2017; 40:422-37. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24:7999-8008. Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, et al. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Med 2002; 1: 183-95. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011; 226: 2484-93. Kim TW, Cho HM, Choi SY, Suguira Y, Hayasaka T, Setou M, et al. (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease. Cell Death Dis 2013;4:e919. Kim H, Kim M, Im SK, Fang S. Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Lab Anim Res 2018; 34:147-159. King AE, Ackley MA, Cass CE, Young JD, and Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 2006;27: 416-25. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004; 5: 63-84. Koscsó B, Csóka B, Selmeczy Z, Himer L, Pacher P, Virág L, Haskó G. Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J Immunol 2012; 188: 445-53. Lalonde R, Strazielle C. Brain regions and genes affecting limb-clasping responses. Brain Res Rev 2011; 67: 252-9. Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci 2016; 19: 623-33. Lee CF, Chern Y. Adenosine receptors and Huntington's disease. Int Rev Neurobiol 2014; 119: 195-232. Lee MR, Ruby CL, Hinton DJ, Choi S, Adams CA, Young Kang N, Choi DS. Striatal adenosine signaling regulates EAAT2 and astrocytic AQP4 expression and alcohol drinking in mice. Neuropsychopharmacology. 2013; 38: 437-45. Li SH, Schilling G, Young WS 3rd, Li XJ, Margolis RL, Stine OC, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993; 11: 985-93. Li XJ, Orr AL, Li S. Impaired mitochondrial trafficking in Huntington's disease. Biochim Biophys Acta 2010; 1802: 62-5. Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres-Aleman I. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J Neurosci 2007; 27: 824-31. Luthi-Carter R, Cha J-HJ. Mechanisms of transcription dysregulation in Huntington’s disease. Clin. Neurosci. Res 2003; 3: 165–77. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506. Marques SC, Humbert S. Huntingtin: here, there, everywhere! J Huntingtons Dis 2013; 2: 395-403. Massachusetts General Hospital (US). (2008, Jul - 2015, Jan). Creatine Safety, Tolerability, Efficacy in Huntington's Disease (CREST-E). Identifier NCT00712426. https://www.clinicaltrials.gov/ct2/show/NCT00712426?term=NCT00712426 draw=2 rank=1 Medivation, Inc. (US). (2009, Jun - 2011, July). A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease. Identifier NCT00920946. https://www.clinicaltrials.gov/ct2/show/NCT00920946?term=NCT00920946 draw=1 rank=1 Meinke G, Bohm A, Hauber J, Pisabarro MT, Buchholz F. Cre Recombinase and Other Tyrosine Recombinases. Chem Rev 2016; 116: 12785-12820. Merit Cudkowicz (MD): Harvard Medical School (US). (2006, Apr – 2008, Nov). Pilot Study of Minocycline in Huntington's Disease. Identifier NCT00277355. https://www.clinicaltrials.gov/ct2/show/NCT00277355?term=NCT00277355 draw=2 rank=1 Mitrovic N, Zaric M, Drakulic D, Martinovic J, Stanojlovic M, Sevigny J. 7beta-Estradiol upregulates ecto-5'-nucleotidase (CD73) in hippocampal synaptosomes of female rats through action mediated by estrogen receptor-alpha and -beta. Neuroscience 2016; 324: 286-96. Morrow RM, Picard M, Derbeneva O, Leipzig J, McManus MJ, Gouspillou G et al.. Mitochondrial energy deficiency leads to hyperproliferation of skeletal muscle mitochondria and enhanced insulin sensitivity. Proc Natl Acad Sci USA 2017; 114: 2705-10. Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, Skepper JN. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 2016; 33: 331-41. Naes SM, Ab-Rahim S, Mazlan M, Abdul Rahman A. Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles. Biomed Res Int 2020; 2020:5197626. Neurocrine Biosciences (US). (2019, Nov - ). Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease. Identifier NCT04102579. https://www.clinicaltrials.gov/ct2/show/NCT04102579?term=NCT04102579 draw=2 rank=1 Nishizaki, T. ATP- and adenosine-mediated signaling in the central nervous system: adenosine stimulates glutamate release from astrocytes via A2a adenosine receptors. J Pharmacol Sci 2004; 94: 100-02. Nold CS. Huntington disease. JAAPA 2017; 30: 46-47. Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A. The Role of Microglia and Astrocytes in Huntington's Disease. Front Mol Neurosci 2019; 12: 258. Pastor-Anglada M, Pérez-Torras S. Emerging Roles of Nucleoside Transporters. Front Pharmacol 2018; 9: 606. Pfizer Inc. (US). (2014, Sep – 2016, Oct). Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease. Identifier NCT02197130. https://www.clinicaltrials.gov/ct2/show/NCT02197130?term=NCT02197130 draw=2 rank=1 Porkka-Heiskanen T, Kalinchuk AV. Adenosine, energy metabolism and sleep homeostasis. Sleep Med Rev 2011; 15: 123-35. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999; 6: 99-104. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 2013; 14: 708-21. Prilenia (ISRAEL). (2014, Feb – 2016, Aug). A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease. Identifier NCT02006472. https://www.clinicaltrials.gov/ct2/show/NCT02006472?term=NCT02006472 draw=2 rank=1 Qi X, Disatnik MH, Shen N, Sobel RA, Mochly-Rosen D. Aberrant mitochondrial fission in neurons induced by protein kinase C{delta} under oxidative stress conditions in vivo. Mol Biol Cell 2011; 22: 256-65. Rangel-Barajas C, Rebec GV. Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences. Curr Protoc Neurosci 2018; 83: e47. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 2008; 23: 1100-7. Rega S, Stiewe T, Chang DI, Pollmeier B, Esche H, Bardenheuer W. Identification of the full-length huntingtin-interacting protein p231HBP/HYPB as a DNA-binding factor. Mol Cell Neurosci 2001 ; 18: 68-79. Robillard KR, Bone DB, Hammond JR. Hypoxanthine uptake and release by equilibrative nucleoside transporter 2 (ENT2) of rat microvascular endothelial cells. Microvasc Res; 75: 351-7. Roepstorff C, Thiele M, Hillig T, Pilegaard H, Richter EA, Wojtaszewski JF. Higher skeletal muscle alpha2AMPK activation and lower energy charge and fat oxidation in men than in women during submaximal exercise. J Physiol 2006; 574: 125-38. Rodrigues FB, Wild EJ. Huntington's Disease Clinical Trials Corner: September 2017. J Huntingtons Dis 2017; 6: 255-63. Rodrigues FB, Wild EJ. Huntington's Disease Clinical Trials Corner: February 2018. J Huntingtons Dis 2018; 7: 89-98. Rodrigues FB, Wild EJ. Huntington's Disease Clinical Trials Corner: April 2020. J Huntingtons Dis 2020; 9: 185-97. Ryter SW, Choi AMK. Cell Death and Repair in Lung Disease. Pathobiology of Human Disease 2014; 2558-74. Scholz J, Niibori Y, W Frankland P, P Lerch J. Rotarod training in mice is associated with changes in brain structure observable with multimodal MRI. Neuroimage 2015; 107:182-9. Schulte J, Littleton JT. The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology. Curr Trends Neurol 2011; 5: 65-78. Sebastião AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996; 48: 167-89. Sharer JD. The adenine nucleotide translocase type 1 (ANT1): a new factor in mitochondrial disease. IUBMB Life 2005; 57: 607-14. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 2011; 20: 1438-55. Siena Biotech S.p.A. (Italy). (2011, Nov – 2012, Oct). A Phase II Safety and Tolerability Study With SEN0014196. Identifier NCT01521585. https://www.clinicaltrials.gov/ct2/show/NCT01521585?term=NCT01521585 draw=2 rank=1 Sitarz KS, Yu-Wai-Man P, Pyle A, Stewart JD, Rautenstrauss B, Seeman P, et al. MFN2 mutations cause compensatory mitochondrial DNA proliferation. Brain 2012; 135 : e219, 1-3; author reply e220, 1-3. Snowden JS. The Neuropsychology of Huntington's Disease. Arch Clin Neuropsychol 2017; 32: 876-887. Sperlagh B, and Vizi ES. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects. Curr Top Med Chem 2011; 11: 1034-46. Studer FE, Fedele DE, Marowsky A, Schwerdel C, Wernli K, Vogt K, et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006; 142: 125-37. Teva Branded Pharmaceutical Products R D, Inc. (US). (2013, Aug – 2014, Dec). First Time Use of SD-809 in Huntington Disease (First-HD). Identifier NCT01795859. https://www.clinicaltrials.gov/ct2/show/NCT01795859?term=NCT01795859 draw=2 rank=1 Teva Branded Pharmaceutical Products R D, Inc. (US). (2014, Oct – 2018, Jun). A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod. Identifier NCT02215616. https://www.clinicaltrials.gov/ct2/show/NCT02215616?term=NCT02215616 draw=2 rank=1 Trushina E, Dyer RB, Badger JD 2nd, Ure D, Eide L, Tran DD, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 2004; 24: 8195-209. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci 2014; 17:694-703. Toyama EQ, Herzig S, Courchet J, Lewis TL, Jr, Losón OC, Hellberg K, et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 2016; 351: 275-81. UniQure Biopharma B.V. (Amsterdam). (2019, Sep - ). Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease. Identifier NCT04120493. https://www.clinicaltrials.gov/ct2/show/NCT04120493?term=NCT04120493 draw=2 rank=1 Vaccinex Inc. (US). (2015, Jul – 2020, Aug). A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503). Identifier NCT02481674. https://www.clinicaltrials.gov/ct2/show/NCT02481674?term=NCT02481674 draw=2 rank=1 Varani K, Rigamonti D, Sipione S, Camurri A, Borea PA, Cattabeni F, et al. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J 2001; 15: 1245-7. Vuong K, Canning CG, Menant JC, Loy CT. Gait, balance, and falls in Huntington disease. Handb Clin Neurol 2018; 159: 251-60. Ward JL, Sherali A, Mo ZP, Tse CM. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 2000; 275: 8375-81. Wave Life Sciences Ltd. (US). (2017, Jul - ). Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (PRECISION-HD1). Identifier NCT03225833. https://www.clinicaltrials.gov/ct2/show/NCT03225833?term=NCT03225833 draw=2 rank=1 Wave Life Sciences Ltd. (US). (2017, Jul - ). Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease. Identifier NCT03225846. https://www.clinicaltrials.gov/ct2/show/NCT03225846?term=NCT03225846 draw=2 rank=1 Wennberg AM, Savica R, Mielke MM. Association between Various Brain Pathologies and Gait Disturbance. Dement Geriatr Cogn Disord 2017; 43: 128-143. Wu J, Lee MR, Choi S, Kim T, Choi DS. ENT1 regulates ethanol-sensitive EAAT2 expression and function in astrocytes. Alcohol Clin Exp Res 2010; 34: 1110-7. Wu, KC, Lee CY, Chou FY., Chern Y, and Lin CJ. Deletion of equilibrative nucleoside transporter-2 protects against lipopolysaccharide-induced neuroinflammation and blood-brain barrier dysfunction in mice. Brain Behav Immun 2020; 84: 59-71. Wu, KC, Lee CY, Chern Y, and Lin CJ. Lipopolysaccharide-induced cognitive impairment is ameliorated via modulating glutamatergic pathways in equilibrative nucleoside transporter-2 knockout mice. (Submitted, 2021) Wu, L., Zhang, L., Li, B., Jiang, H., Duan, Y., Xie, Z. AMP-Activated Protein Kinase (AMPK) Regulates Energy Metabolism through Modulating Thermogenesis in Adipose Tissue. Front Physiol2018; 9: 122. Yaguchi T, and Nishizaki T. Extracellular high K+ stimulates vesicular glutamate release from astrocytes by activating voltage-dependent calcium channels. J Cell Physiol 2010; 225: 512-18. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, et al. Huntingtin inhibits caspase-3 activation. EMBO J 2006; 25: 5896-906. Zimmermann H. Ectonucleotidases in the nervous system. Novartis Found Symp 2006; 276:113-28; discussion 128-30, 233-7, 275-81. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003; 35: 76-83. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77041 | - |
| dc.description.abstract | 亨丁頓舞蹈症是一種顯性體染色體遺傳疾病，源於位於第四對染色體上的亨丁頓基因具有過長的CAG重複序列，因而產生變異的且有毒的亨丁頓蛋白。目前對於亨丁頓舞蹈症並無有效的延緩疾病或是治癒的方法，只能給予支持性的治療。腺苷在腦中的基礎調控機制中扮演很重要的角色。近期有許多研究發現在亨丁頓舞蹈症的病人腦中及疾病小鼠的腦中，腺苷的恆定有被異常調控的現象。而在腦中主要維持腺苷恆定的兩種轉運蛋白為平衡型核苷轉運蛋白1及2 (Ent1及Ent2)，其中又以Ent2在腦中的表現量較多。本研究的目的在探討基因剔除Ent2對於亨丁頓症小鼠(R6/2)疾病進展之影響。剔除Ent2的R6/2小鼠(R6/2-Ent2-/-)以及其同窩對照組( R6/2-Ent2+/+)經由R6/2-Ent2+/-小鼠及CBA-Ent2+/-小鼠配對而得。而R6/2-Ent2+/-以及CBA-Ent2+/-小鼠則分別經由配對CBA-Ent2-/- 與R6/2 小鼠以及配對Ent2-/- (C57BL/6-Slc29a2em1) 與CBA (CBA/CaJNarl)小鼠而得。小鼠之運動功能以滾輪運動測試、四肢緊縮測驗以及步態分析等行為測試評估。除此之外，也記錄其生命週期。結果顯示將平衡型核苷轉運蛋白2剔除後，R6/2小鼠無論在滾輪運動測試、四肢緊縮測驗及生命週期等方面皆具有惡化現象。雖然確切影響機致仍有待釐清，本研究的結果顯示平衡型核苷轉運蛋白2在亨丁頓氏症的疾病進展上扮演重要角色。 | zh_TW |
| dc.description.abstract | Huntington’s disease (HD) is an inherited autosomal dominant disorder caused by mutant huntingtin protein translated from HTT gene with an expansion of CAG repeats in the exon1.To date, the treatment of HD is still an unmet medical need. Adenosine plays an important role in modulating several functions in the brain, while recent studies have shown that adenosine homeostasis is aberrantly regulated in the brain of animal models and patients of HD. Equilibrative nucleoside transporter 1 (Ent1) and Ent2 are the major transporters responsible for brain uptake of adenosine, in which the expression of Ent2 is generally higher than that of Ent1. The objective of the present study was to investigate the impacts of Ent2 knockout on disease progression of a mouse model of HD (R6/2 mice). R6/2-Ent2-/- mice and the littermate controls (i.e., R6/2-Ent2+/+) were obtained by crossing R6/2-Ent2+/- mice with CBA-Ent2+/-. R6/2-Ent2+/- and CBA-Ent2+/- mice were obtained by crossing CBA-Ent2-/- mice and R6/2 mice and by crossing Ent2-/- (C57BL/6-Slc29a2em1) and CBA (CBA/CaJNarl), respectively. Motor function was evaluated by rotarod performance, limb-clasping score, and gait analysis. Also, lifespan was recorded. The results showed the Ent2 deletion caused detrimental effects on the rotarod performance, limb-clasping, and gait function. It also tended to decrease lifespan of R6/2 mice. Although the mechanisms underlying these effects are to be verified, these results suggest that Ent2 plays an important role in disease progression of R6/2 mice. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-10T21:44:21Z (GMT). No. of bitstreams: 1 U0001-0202202115104000.pdf: 5867273 bytes, checksum: 2e587876b564e7724862a52a6f6e5f4f (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 誌謝 I 摘要 II Abstract III Table of Contents IV List of Figures VI List of Tables IX Chapter 1 Literature review 1 1.1 Huntington’s disease 1 1.2 Animal models and behavioral tests used for HD research 7 1.3 Adenosine in the brain 11 1.4 Alterations of striatal adenosine tone in HD 14 Chapter 2 Objectives 23 Chapter 3 Materials and methods 24 3.1 Animals 24 3.2 Genotyping 25 3.3 Behavioral tests 26 3.4 Immunofluorescence staining 27 3.5 Statistical analysis 28 Chapter 4 Results 29 4.1 Genotyping of R6/2-Ent2 mice 29 4.2 Examination of Ent2 knockout on the phenotypes and pathological features of HD mice with 170Q and 230Q 29 Chapter 5 Discussion 64 Chapter 6 Conclusion 69 Chapter 7 References 70 Chapter 8 Supplements 83 | |
| dc.language.iso | en | |
| dc.subject | 亨丁頓氏舞蹈症 | zh_TW |
| dc.subject | 平衡型核苷轉運蛋白2 | zh_TW |
| dc.subject | Huntington's disease | en |
| dc.subject | equilibrative nucleoside transporter 2 | en |
| dc.title | 研究基因剔除平衡型核苷轉運蛋白2對亨丁頓舞蹈症模式的小鼠疾病進程的影響 | zh_TW |
| dc.title | Investigation of the impacts on genetic removal of equilibrative nucleoside transporter-2 on disease progression of a mouse model of Huntington’s disease | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳儀莊(Yi-Juang Chern),徐嘉琳(Chia-Lin Hsu) | |
| dc.subject.keyword | 亨丁頓氏舞蹈症,平衡型核苷轉運蛋白2, | zh_TW |
| dc.subject.keyword | Huntington's disease,equilibrative nucleoside transporter 2, | en |
| dc.relation.page | 86 | |
| dc.identifier.doi | 10.6342/NTU202100386 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2021-02-03 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0202202115104000.pdf 未授權公開取用 | 5.73 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。